Algert Global’s Alnylam Pharmaceuticals ALNY Stock Holding History

Algert Global’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-580	Closed	-$231K	–	1144
2025 Q4	$231K	Buy	+580	New	+$257K	﹤0.01%	1041
2025 Q2	–	Sell	-1,150	Closed	-$311K	–	1175
2025 Q1	$311K	Buy	+1,150	New	+$296K	0.01%	1002
2024 Q4	–	Sell	-9,825	Closed	-$2.7M	–	1162
2024 Q3	$2.7M	Buy	9,825 +7,865	+401%	+$2.05M	0.07%	454
2024 Q2	$476K	Buy	+1,960	New	+$309K	0.02%	934

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Algert Global's ALNY Position: Q1 2026 in Review

Algert Global sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 580 shares — an estimated $231K sold.

Algert Global first reported a position in ALNY in Q2 2024 and held it in 4 quarters. The position peaked at $2.7M in Q3 2024. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Algert Global reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Algert Global sold 580 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $231K.
Algert Global first reported a position in Alnylam Pharmaceuticals in Q2 2024 and held it in 4 quarters.
Algert Global's Alnylam Pharmaceuticals position peaked at $2.7M in Q3 2024.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.